Janusz Puc
Research Subjects
Janusz Puc has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Irene M. Min
Department of Radiology, Houston Methodist Research Institute, Houston, Texas
9 shared publications - Moonsoo M. Jin
Department of Radiology, Houston Methodist Research Institute, Houston, Texas
9 shared publications - Aidan C. Burnett
Department of Radiology, Houston Methodist Research Institute, Houston, Texas
8 shared publications - Bing He
Weill Cornell Medicine 5 Department of Pathology and Laboratory Medicine New York, New York
8 shared publications - Dessislava Stefanova
Weill Cornell Medicine 3 Department of Surgery New York, New York
8 shared publications - Diella S. Babu
Department of Radiology, Houston Methodist Research Institute, Houston, Texas
8 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
HLA dependence of engineered T-cell populations quantified as Δ target viability
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
HLA dependence of engineered T-cell populations quantified as Δ target viability
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Phenotypic analysis of engineered T cells
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Phenotypic analysis of engineered T cells
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S14 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Phenotypes of RM-ATC and donor-matched primary T cells
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Phenotypes of RM-ATC and donor-matched primary T cells
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Increased NFAT activity mounted by TCR-8505C/ICCR expression
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Increased NFAT activity mounted by TCR-8505C/ICCR expression
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Generation of 8505C-OKT3 cells
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Generation of 8505C-OKT3 cells
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
TCRa depletion in ICCR-T cells
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
TCRa depletion in ICCR-T cells
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Conjugate analysis of engineered T cells and IFNγ-prestimulated A375-MA2 cells
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Conjugate analysis of engineered T cells and IFNγ-prestimulated A375-MA2 cells
- 8 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (7) , OF1-OF17
An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-Cell Function
Engineered T-cell therapies, such as chimeric antigen receptor (CAR)– and T-cell receptor (TCR)–based approaches, have transformed outcomes in hematologic malignancies, yet their efficacy in solid tumors remains limited by tumor antigen escape, immunosuppressive microenvironments, and insufficient activation of CAR or TCR signaling. To overcome these barriers, we developed an intercellular adhesion molecule 1 (ICAM1)–specific chimeric costimulatory receptor (ICCR) engineered for expression in T cells to augment their activation. ICAM1 is broadly expressed across solid tumors and is further upregulated by IFNγ released during early T-cell engagement, creating a feed-forward loop that reinforces tumor recognition. ICCR engagement with ICAM1 triggered NF-κB signaling independently of TCR–peptide (p)/MHC engagement; however, full T-cell activation and cytotoxic function remained dependent on intact TCR signaling. In primary T cells, ICCR increased proliferation, cytokine production, and cytotoxicity, resulting in improved tumor control in two anaplastic thyroid cancer xenograft models treated with allogeneic or autologous ICCR-T cells. Mechanistically, ICCR strengthened tumor cell engagement, promoted selection and expansion of tumor-specific TCR clonotypes, and amplified downstream signaling pathways. These findings identify ICCR as a strategy that leverages an immune synapse–mimetic mechanism to enhance the function of low-activity tumor-specific TCRs and improve T-cell responses in solid tumor microenvironments.
- 8 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (7) , OF1-OF17
An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-Cell Function
Engineered T-cell therapies, such as chimeric antigen receptor (CAR)– and T-cell receptor (TCR)–based approaches, have transformed outcomes in hematologic malignancies, yet their efficacy in solid tumors remains limited by tumor antigen escape, immunosuppressive microenvironments, and insufficient activation of CAR or TCR signaling. To overcome these barriers, we developed an intercellular adhesion molecule 1 (ICAM1)–specific chimeric costimulatory receptor (ICCR) engineered for expression in T cells to augment their activation. ICAM1 is broadly expressed across solid tumors and is further upregulated by IFNγ released during early T-cell engagement, creating a feed-forward loop that reinforces tumor recognition. ICCR engagement with ICAM1 triggered NF-κB signaling independently of TCR–peptide (p)/MHC engagement; however, full T-cell activation and cytotoxic function remained dependent on intact TCR signaling. In primary T cells, ICCR increased proliferation, cytokine production, and cytotoxicity, resulting in improved tumor control in two anaplastic thyroid cancer xenograft models treated with allogeneic or autologous ICCR-T cells. Mechanistically, ICCR strengthened tumor cell engagement, promoted selection and expansion of tumor-specific TCR clonotypes, and amplified downstream signaling pathways. These findings identify ICCR as a strategy that leverages an immune synapse–mimetic mechanism to enhance the function of low-activity tumor-specific TCRs and improve T-cell responses in solid tumor microenvironments.
- Open Access
Chimeric Antigen Receptor T Cell Therapy Targeting Epithelial Cell Adhesion Molecule in Gastric Cancer: Mechanisms of Tumor Resistance
Epithelial cell adhesion molecule (EpCAM) is a tumor-associated antigen that is frequently overexpressed in various carcinomas. We have developed chimeric antigen receptor (CAR) T cells specifically targeting EpCAM for the treatment of gastric cancer. This study sought to unravel the precise mechanisms by which tumors evade immune surveillance and develop resistance to CAR T cell therapy. Through a combination of whole-body CAR T cell imaging and single-cell multiomic analyses, we uncovered intricate interactions between tumors and tumor-infiltrating lymphocytes (TILs). In a gastric cancer model, tumor-infiltrating CD8 T cells exhibited both cytotoxic and exhausted phenotypes, while CD4 T cells were mainly regulatory T cells. A T cell receptor (TCR) clonal analysis provided evidence of CAR T cell proliferation and clonal expansion within resistant tumors, which was substantiated by whole-body CAR T cell imaging. Furthermore, single-cell transcriptomics showed that tumor cells in mice with refractory or relapsing outcomes were enriched for genes involved in major histocompatibility complex (MHC) and antigen presentation pathways, interferon-γ and interferon-α responses, mitochondrial activities, and a set of genes (e.g., CD74, IDO1, IFI27) linked to tumor progression and unfavorable disease prognoses. This research highlights an approach that combines imaging and multiomic methodologies to concurrently characterize the evolution of tumors and the differentiation of CAR T cells.
Open AccessChimeric Antigen Receptor T Cell Therapy Targeting Epithelial Cell Adhesion Molecule in Gastric Cancer: Mechanisms of Tumor Resistance
Epithelial cell adhesion molecule (EpCAM) is a tumor-associated antigen that is frequently overexpressed in various carcinomas. We have developed chimeric antigen receptor (CAR) T cells specifically targeting EpCAM for the treatment of gastric cancer. This study sought to unravel the precise mechanisms by which tumors evade immune surveillance and develop resistance to CAR T cell therapy. Through a combination of whole-body CAR T cell imaging and single-cell multiomic analyses, we uncovered intricate interactions between tumors and tumor-infiltrating lymphocytes (TILs). In a gastric cancer model, tumor-infiltrating CD8 T cells exhibited both cytotoxic and exhausted phenotypes, while CD4 T cells were mainly regulatory T cells. A T cell receptor (TCR) clonal analysis provided evidence of CAR T cell proliferation and clonal expansion within resistant tumors, which was substantiated by whole-body CAR T cell imaging. Furthermore, single-cell transcriptomics showed that tumor cells in mice with refractory or relapsing outcomes were enriched for genes involved in major histocompatibility complex (MHC) and antigen presentation pathways, interferon-γ and interferon-α responses, mitochondrial activities, and a set of genes (e.g., CD74, IDO1, IFI27) linked to tumor progression and unfavorable disease prognoses. This research highlights an approach that combines imaging and multiomic methodologies to concurrently characterize the evolution of tumors and the differentiation of CAR T cells.
- Top Cited Papers
- 1 April 2021
- Published by Elsevier in Cancer Cell
- Vol. 39 (4) , 566-579.e7
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress
- 1 April 2021
- Published by Elsevier in Cancer Cell
- Vol. 39 (4) , 566-579.e7
Top Cited PapersTherapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress